Trevor M. Feinstein, MD, explained how quality of life was improved for patients with stage IIIB/IV EGFR wild-type non-small cell lung cancer receiving plinabulin in addition to docetaxel in the DUBLIN-3 phase 3 trial.
At 2022 Annual Meeting of the American Society for Clinical Oncology (ASCO)Trevor M. Feinstein, MD, medical oncologist in hematology and internal medicine at Piedmont Cancer Institute in Atlanta, Georgia, spoke to CancerNetwork® about the Phase 3 DUBLIN-3 trial (NCT02504489) which analyzed patients with of EGFR wild-type stage IIIB/IV non-small cell lung cancer receiving docetaxel with or without plinabulin.1.2 The results of the trial indicated that patients in the plinabulin group had better results in terms of efficacy and safety. Quality of life, as measured using the European Organization for the Research and Treatment of Cancer Core Quality of Life Core 30 (QLQ-C30) questionnaire and the Lung Cancer Modular Supplement QLQ-LC13, was also improved with the addition of plinabulin to docetaxel.
There were 2 ways we looked at quality of life. At ESMO [the European Society for Medical Oncology Congress]we introduced QTWiST, which is a symptom-free quality-adjusted time [of disease of toxicity] before progress.3 We saw that with the addition of plinabulin to docetaxel, the QTWiST quality of life increased by more than 18%. Now, at this year’s ASCO, we looked at patient-reported quality of life outcomes and the 2 different measures therein. During the first 10 cycles, we found no difference in quality of life. Between cycles 10 and 20 you start to see the curve separate and by cycle 20 they have become significant. Now we have seen that patients who received plinabulin had less cough, dysphasia and sore throat. You saw this with the extra plinabulin and there was an increase in hemoptysis. What I also found interesting was that patients who received plinabulin received more docetaxel cycles and no increase in neuropathy was reported despite the number of docetaxel cycles. Otherwise, the quality of life we saw earlier at ESMO [resulted in] decrease in neutropenia with the addition of plinabulin.
- Feinstein T, Ogenstad S, Mitchell D, et al. DUBLIN-3 Results on Quality of Life (QoL) in Patients with Second-/Third-Line EGFR Wild-Type NSCLC Receiving Docetaxel (Doc) With or Without Plinabulin (Plin) Using Validated EORTC QLQ C30 Questionnaires and QLQ LC13. J Clin Oncol. 2022;40(supplement 16):9091. doi:10.1200/JCO.2022.40.16_suppl.9091
- Han B, Feinstein T, Shi Y et al. Subgroup analysis in patients (pts) with non-squamous cell (N-Sq), EGFR-wild-type (wt), second/third-line NSCLC from the global Phase (Ph) 3 DUBLIN-3 trial (BPI-2358-103) with the combination plinabulin/docetaxel (Plin/Doc) versus Doc alone. J Clin Oncol. 2022;40(supplement 16):9090. doi:10.1200/JCO.2022.40.16_suppl.9090
- Feinstein T, Han B, Shi Y et al. DUBLIN-3 (BPI-2358-103): A global Phase (Ph) III trial of the combination plinabulin/docetaxel (Plin/Doc) versus Doc in 2nd/3rd line (pts) NSCLC patients with EGFR of wild-type (wt) progressing on an earlier platinum-based diet. Annale Oncol. 2021;32(supplement 5):S1283-S1246. doi:10.1016/announce/announce741